𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma

✍ Scribed by James C. Arseneau; Janet M. Wolter; Mario Kuperminc; John C. Ruckdeschel

Publisher
Springer US
Year
1983
Tongue
English
Weight
240 KB
Volume
1
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of high-dose tamoxifen (N
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma
✍ Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 206 KB πŸ‘ 3 views

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reas

Interferon in combination with vinblasti
Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study
✍ Stein Gundersen; A. Flokkmann πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 288 KB πŸ‘ 2 views

Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (a-IFN) and vinblastine (VBL). The a-IFN was administered subcutaneously daily at an initial dose of 3 X lo6 IU escalating to a maximal dose of 9 X lo6 U daily for the first 10 weeks fol

Phase II study of subcutaneously adminis
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma
✍ Bellet, Robert E. ;Catalano, R. B. ;Mastrangelo, Michael J. ;Berd, David πŸ“‚ Article πŸ“… 1978 πŸ› John Wiley and Sons 🌐 English βš– 268 KB

## Abstract Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m^2^/day for 10 days. Twenty‐six (26) patients were evaluab